ELAC2 polymorphisms and prostate cancer risk: A meta-analysis based on 18 case-control studies

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 3, 2010, Pages 270-277

  Xu, B ^a   Tong, N ^a   Li, J M ^a   Zhang, Z D ^a   Wu, H F ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

ELAC2 HPC2; Meta analysis; Polymorphism; Risk

Indexed keywords

ALANINE; ELAC HOMOLOG 2; LEUCINE; PROTEIN ELAC2; SERINE; THREONINE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AFRICAN; ALLELE; ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; ETHNICITY; FAMILIAL CANCER; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PUBLISHING; RACE DIFFERENCE; SPORADIC PROSTATE CANCER;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77955718197     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.6     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Pienta KJ, Esper PS. Is dietary fat a risk factor for prostate cancer? J Natl Cancer Inst 1993; 85: 1538-1540.
3. Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett; (e-pub ahead of print 15 January 2010).
4. Imamoto T, Suzuki H, Utsumi T, Endo T, Takano M, Yano Met al. Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol 2009; 5: 1005-1013.
5. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-3371.
6. Ghadirian P, Howe GR, Hislop TG, Maisonneuve P. Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer 1997; 70: 679-681.
7. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 2002; 90: 174-184. (Pubitemid 34779588)
8. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27: 172-180.
9. Takaku H, Minagawa A, Takagi M, Nashimoto M. A candidate prostate cancer susceptibility gene encodes tRNA 30 processing endoribonuclease. Nucleic Acids Res 2003; 31: 2272-2278.
10. Korver W, Guevara C, Chen Y, Neuteboom S, Bookstein R, Tavtigian S et al. The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex. Int J Cancer 2003; 104: 283-288.
11. Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M et al. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 2001; 68: 912-917.
12. Camp NJ, Tavtigian SV. Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am J Hum Genet 2002; 71: 1475-1478.
13. Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Neufing P et al. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst 2003; 95: 818-824.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
16. Adler D, Kanji N, Trpkov K, Fick G, Hughes RM. HPC2/ELAC2 gene variants associated with incident prostate cancer. J Hum Genet 2003; 48: 634-638.
17. Fujiwara H, Emi M, Nagai H, Nishimura T, Konishi N, Kubota Y et al. Association of common missense changes in ELAC2 (HPC2) with prostate cancer in a Japanese case-control series. J Hum Genet 2002; 47: 641-648.
18. Meitz JC, Edwards SM, Easton DF, Murkin A, Ardern-Jones A, Jackson RA et al. HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br J Cancer 2002; 87: 905-908.
19. Noonan-Wheeler FC, Wu W, Roehl KA, Klim A, Haugen J, Suarez BK et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate 2006; 66: 49-56.
20. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000; 67: 1014-1019.
21. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ,Walker AH, Spangler E et al. Association of susceptibility alleles in ELAC2/ HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 2005; 14: 949-957.
22. Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T et al. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate 2008; 68: 1790-1797.
23. Shea PR, Ferrell RE, Patrick AL, Kuller LH, Bunker CH. ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago. Hum Genet 2002; 111: 398-400.
24. Stanford JL, Sabacan LP, Noonan EA, Iwasaki L, Shu J, Feng Z et al. Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study. Cancer Epidemiol Biomarkers Prev 2003; 12: 876-881.
25. Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK et al. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 2001; 61: 4982-4984.
26. Suzuki K, Ohtake N, Nakata S, Takei T, Matsui H, Ono Y et al. Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population. Anticancer Res 2002; 22: 3507-3511.
27. Takahashi H, Lu W, Watanabe M, Katoh T, Furusato M, Tsukino H et al. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Int J Cancer 2003; 107: 224-228.
28. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF et al. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001; 61: 6494-6499.
29. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J et al. Evaluation of linkage and association of HPC2/ ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001; 68: 901-911.
30. Yokomizo A, Koga H, Kinukawa N, Tsukamoto T, Hirao Y, Akaza H et al. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate 2004; 61: 248-252. (Pubitemid 39350447)
31. Rokman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA et al. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001; 61: 6038-6041.
32. Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX et al. Interleukin10 -592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci; (e-pub ahead of print 11 August 2009).
33. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279: 281-286.
34. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992; 267: 374-378.
35. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-872.